Anika Therapeutics, Inc. — Q1 2014 Form 10-Q Summary
Business context and reporting period
Anika develops, manufactures, and commercializes hyaluronic-acid-based products for tissue protection, healing, and repair, including orthobiologics, dermal, surgical, ophthalmic, and veterinary products. This unaudited Form 10-Q covers the three months ended March 31, 2014, compared with the three months ended March 31, 2013. The company reports one operating segment.
Key financial metrics
| Metric | Q1 2014 | Q1 2013 | Change |
|---|---|---|---|
| Total revenue | $34.0 million | $15.2 million | Up 123% |
| Product revenue | $14.4 million | $14.5 million | Down 1% |
| Licensing, milestone and contract revenue | $19.7 million | $0.8 million | Up 2,512% |
| Income from operations | $23.9 million | $5.0 million | Up 376% |
| Net income | $15.0 million | $3.1 million | Up 390% |
| Diluted earnings per share | $0.97 | $0.21 | Up $0.76 |
| Product gross profit | $10.0 million | $9.7 million | Up 3% |
| Product gross margin | 70% | 67% | Up 3 percentage points |
| Net cash from operating activities | $13.6 million | $6.1 million | Up $7.5 million |
Reported operating margin was approximately 70% and net margin approximately 44%, both substantially elevated by MONOVISC-related milestone and deferred-revenue recognition. Research and development expense increased 45% to $2.3 million, while SG&A decreased 12% to $3.5 million. The effective tax rate was 37%, compared with 38% in the prior-year quarter.
Cash and cash equivalents were $82.2 million at March 31, 2014, up from $63.3 million at December 31, 2013. Working capital was approximately $105.8 million, compared with $85.3 million at year-end. The balance sheet presents no debt balance or principal payments during the quarter. Total liabilities were $17.5 million and stockholders’ equity was $156.6 million.
Material changes versus the prior comparable period
- MONOVISC-related licensing, milestone, and contract revenue totaled $19.65 million, including a $17.5 million milestone payment and recognition of the remaining $2.2 million deferred balance from the 2011 upfront payment.
- The revenue recognition followed FDA approval of MONOVISC on February 25, 2014 and resolution of the related Genzyme patent litigation.
- Product revenue was broadly stable, with orthobiologics up 3% and surgical revenue up 77%, offset by declines in dermal, ophthalmic, and veterinary products.
- Ophthalmic revenue fell 78% because Bausch & Lomb delayed contractual minimum purchases until the fourth quarter of 2014. Veterinary revenue declined 40%, primarily due to distributor order timing.
- Research and development spending increased primarily because of the CINGAL Phase III clinical trial, for which enrollment was completed in February 2014.
- Cash increased by $18.8 million, supported by operating cash flow, stock-option exercise proceeds, and a $4.4 million tax benefit from stock-option exercises.
Guidance, outlook, risks, contingencies, and unusual items
- The first U.S. commercial sale of MONOVISC occurred on April 15, 2014. Anika received a subsequent $5 million milestone payment, expected to be recognized as revenue in the second quarter of 2014.
- Management expects 2014 revenue growth in joint-health, dermal, and surgical products, but expects ophthalmic revenue to decline under the current Bausch & Lomb supply agreement. Management also expects increased R&D and SG&A expense.
- Management expects to submit the CINGAL CE Mark application by December 31, 2014, or shortly thereafter, subject to completion and evaluation of the clinical and regulatory process.
- Management stated that available cash and internally generated funds are adequate to support the business for the next twelve months. Future cash needs could increase with expanded operations, development programs, and capital expenditures; additional financing may be required if existing resources are insufficient.
- The Genzyme patent lawsuit was dismissed with prejudice on March 10, 2014. Other ordinary-course legal proceedings remain, but management does not expect them to have a material adverse effect.
- Key risks include regulatory approvals, clinical-trial outcomes, commercialization and reimbursement, competition, intellectual-property protection, dependence on distribution partners, foreign-currency exposure, manufacturing execution, and reliance on key personnel.
- Inventory increased to $13.0 million from $11.0 million at year-end, including a substantial increase in finished goods, reflecting anticipated future demand.
- The quarter included significant nonrecurring MONOVISC revenue; therefore, reported revenue, margins, and earnings are not representative of underlying recurring product performance.
Important facts for investors to verify
- Whether MONOVISC U.S. launch volumes and subsequent milestone or sales-based payments develop as expected.
- The sustainability of product revenue and the 70% product gross margin excluding favorable product mix and launch-related effects.
- The timing and outcome of the CINGAL regulatory submission and any future clinical or regulatory requirements.
- The impact of delayed ophthalmic purchases and distributor order timing on full-year product revenue.
- Cash conversion after the one-time MONOVISC milestone, inventory build, taxes, and increased development spending.
- Potential future intellectual-property, regulatory, reimbursement, and commercial-partner risks, including risks described in the company’s 2013 Form 10-K.